



Immun-
Onkologische
Forschung

IOZK Stiftung

In focus:
The Immuno-
Oncological
Research



Immun-
Onkologische
Forschung

IOZK Stiftung

Foundation for immuno-oncological research IOZK non profit organization
Hohenstaufenring 30-32, 50674 Köln, +49 (0)221-420 399 25,
E-Mail: info@iozk-stiftung.org, www.iozk-stiftung.org
Donation account: Volksbank Köln, IBAN: DE29 3806 0186 8304 2140 16, BIC: GENODED1BRS
Paypal: donation@iozk-stiftung.org

The Goal:

More awareness and focused research
for the patients' well-being

By now, immunotherapy is an additional treatment option for oncology. However, a lot of people don't know about this possibility and thus can't profit from the innovative procedures and opportunities.

Therefore it is a fundamental goal of the foundation to spread information about these specialized topics. The main purpose of the foundation is to conduct specific research and to put the results into practice within short time so that people suffering from cancer can already receive this help today.



The Therapy:


A treatment of cancer that helps the body to help itself

The immune system keeps our body healthy and protects us not only from infections, but also from the growth of malignant cells. With modern scientific discoveries, we can better use the power and diversity of the immune system to treat cancer.

By now, pharmaceutical companies can produce substances like antibodies for successful immunologic treatment options. However, this kind of treatment comprises but a small part of the possibilities of immunotherapy. Today we constantly learn more about how to activate the immune system in order for it to take action against the tumour cells on its own.

This is why the IOZK Foundation aims to inform about the new possibilities of these forms of treatment focused on the immune system. Cellular immunotherapy allows to create an immune reaction against tumour growth. The goal is to inhibit the growth of the tumour and the development of metastases. This is all about a balance between the immune system and the tumour – it's not necessary to destroy up to the very last cancer cell. The great advantage of such a therapy is that it targets and destroys only the tumour cells, while all healthy cells remain untouched. Therefore, the side effects remain low.

This therapeutic principle can be applied to all solid, malignant tumour diseases. In everyday practice, gynaecological tumours (breast cancer, ovarian or uterine cancer) and urological malignancies (prostate, kidney or bladder cancer) are treated. The spectrum also includes lung, pancreas or liver cancer. One more area of focus is neuro-oncology (various types of brain tumours).



The Foundation: Immuno-Oncological Research

The purpose of the non-profit IOZK Foundation is to foster the scientific fundamentals of immuno-oncologic research. The measures seek to promote the research on therapy options against cancer and the swift translation of their results into practice in accordance with the legal frame.

The foundation supports scientific research projects that focus on developing immunotherapeutic treatments and optimize this form of therapy. To this end, the foundation puts its efforts into the promotion of young researchers, transparency of projects and independence from economic interests.

A further point of focus is external communication and scientific discourse: our participants put their strength into informing the public about cellular immunotherapy and promoting scientific exchange e. g. through public relations, publications and conferences.

The Projects until 2021: Research means finding new answers

- Testing and validating antigen production and antigen presentation
- Antibody production in oncologic virotherapy
- Development of an FAC protocol for the measurement of STATS phosphorylation and T cell proliferation after stimulation with CD3/CD28 antibodies (Test of memory capacity of immune cells)
- Evaluation of specific purity activation markers in human dendritic cells for tumour immunotherapy
- Antigens similar to cancer stem cells from xenogeneic foetal tissue
- Research on natural killer cells, in vitro and in vivo
- Using in vitro CMV-expanded T cells as adaptive T cell therapy

In the future, the work of the foundation will continue to focus on the topics of immunotherapy and keep on optimizing them.

The Donations:

Endowments and donations welcome

The foundation supports the cellular immuno-oncological research. Further, it is meant to serve as a platform for communication and will support networking. This also includes connecting to other organizations. In our scientific projects we seek to especially support young scientists in theory and practice. These activities and standards need according means, resources and possibilities.

From our own organization alone, the IOZK treatment centre, the full achievement of these goals is not possible. This is why we count on the support of individuals or companies that would like to contribute to the immunological research against cancer by bringing financial means to the foundation.

With a donation you support innovative projects of immunotherapy and therefore are part of progress in the research of cancer. Be it a small amount or a large sum – everything counts for the vision of fighting cancer with the help of the immune system so that people can gain a higher quality of life and a longer lifetime.

Scan here
for online donation



The Organization:

About the people behind the foundation

Direction



Dr. Wilfried Stücker



Stefaan Van Gool, MD, PhD

Dr. Wilfried Stücker continues to develop a therapy that, instead of administering a substance from without, strengthens and activates the body's own defence mechanisms to proceed against the tumour tissue.

Stefaan Van Gool, MD, PhD is medical director of translational oncology. He is backed by over 25 years of experience in clinical oncology and tumour immunology, including basic research on these topics.

Management



Dr. Felix Li



Arnd Slegers



Jacob Hösl

Dr. Felix Li graduated with a PhD in Economics from Cologne University. He successfully held leadership roles across Germany and Asia in Retail and Private Equity. He is married and is father of three adult children.

Arnd Slegers looks after the financial needs of the foundation. He has over 20 years of experience in financial management in companies around the world. He is also researching in the area of health economy.

Jacob Hösl is a lawyer with 30 years experience in the area of foundation and company law. He has constantly worked on matters regarding health and patient care – thereby producing various publications.

Scientific advisory



Prof. Dr. rer. nat.
Volker Schirmmacher



Elisabeth Arrojo, MD, PhD



Abhishek D. Garg, MSc. PhD

Prof. Dr. rer. nat. Volker Schirmmacher is an internationally renowned pioneer of cellular immunology and immune therapy specialized in the scientific work with oncolytic viruses.

Elisabeth Arrojo, MD, PhD, is medical director of the Institute of Advanced Oncology in Madrid and professor of oncological hyperthermia at University of Murcia. She was awarded best oncologist of the year in Spain in 2020 and 2021.

Abhishek D. Garg, MSc. PhD. is the assistant professor at KU Leuven, Belgium, and head of the Cell Stress & Immunity Lab. He is an expert in cellular and molecular immunology, especially in the field of immunogenic cell death in cancer.

Contakt

Foundation for immuno-oncological research
IOZK non-profit organization

Hohenstaufenring 30-32
50674 Köln

Tel. +49 (0)221-420 399 25
E-Mail: info@iozk-stiftung.org
www.iozk-stiftung.org

Please contact:

Dr. Felix Li

Tel. +49 (0)221-420 399 25
E-Mail: fli@iozk-stiftung.org

Arnd Slegers

Tel. +49 (0)221-420 399 25
E-Mail: slegers@iozk-stiftung.org